Daiichi Sankyo secures NICE approval for Vanflyta

19 September 2024

Daiichi Sankyo’s (TYO: 4568) today revealed that its Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine National Health Service (NHS) commissioning in England and Wales.

Vanflyta is authorized by the health care assessor for use as an induction, consolidation and maintenance therapy for treating newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML). A clinical study has demonstrated that quizartinib with chemotherapy has been shown to have an improvement in median overall survival of 16.8 months compared to chemotherapy alone in a recent clinical study, representing a significant benefit for patients in an area of unmet need.

According to Daiichi Sankyo, quizartinib is the first selective FLT3 inhibitor licensed in the UK specifically for the treatment of newly diagnosed patients with FLT3-ITD positive AML, which represents about 25% to 30% of all new AML cases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK